SGLT-2 Inhibitors and GLP-1 Agonists Confer a Survival Benefit in Patients with Type 2 Diabetes

Sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 agonists conferred benefit, but dipeptidyl peptidase 4 inhibitors didn't have this effect.

In a meta-analysis of 236 randomized trials (≈176,000 patients; ≥12 weeks' duration), researchers evaluated the survival benefits of three major classes of medications used to treat patients with type 2 diabetes — sodium–glucose cotransporter (SGLT)-2 inhibitors, glucagon-like peptide (GLP)-1 agonists, and dipeptidyl peptidase (DPP)-4 inhibitors. A network analysis was used to compare each class of medications with other classes and with placebo.

Compared with placebo controls, SGLT-2 inhibitors lowered absolute mortality risk significantly by 1.0% (hazard ratio, 0.8); the respective results for GLP-1 agonists were 0.6% and 0.9. SGLT-2 inhibitors and GLP-1 agonists were not significantly different from each other. DPP-4 inhibitors yielded no…

Reviewing Authors

Thomas L. Schwenk, MD

Disclosures

Editorial BoardsUpToDate

Thomas L. Schwenk, MD

Disclosures

Editorial BoardsUpToDate

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

SGLT-2 Inhibitors and GLP-1 Agonists Confer a Survival Benefit in Patients with Type 2 Diabetes

Topics

Reviewing Authors